APPLICATIONS PUBLISHED 18 SEPTEMBER 2002
Published: 1-Mar-2003
The following patent applications are taken from the weekly European Patents Bulletin and give the publication number and date of publication as well as the title of the specification and the applicant. An asterisk denotes that application was made through the International Patent Cooperation Treaty (PCT). Further details on individual patent applications can be obtained from the EPO at Schottenfeldgasse 29, A-1072 Vienna. T +43 1521 260 F +43 1 52126 4492
The following patent applications are taken from the weekly European Patents Bulletin and give the publication number and date of publication as well as the title of the specification and the applicant. An asterisk denotes that application was made through the International Patent Cooperation Treaty (PCT). Further details on individual patent applications can be obtained from the EPO at Schottenfeldgasse 29, A-1072 Vienna. T +43 1521 260 F +43 1 52126 4492
Devices for the delivery of drugs having antiprogestinic properties
Leiras 1239829*
Dosage forms having a barrier layer to laser ablation
Alza 1239830*
Improved pharmaceutical compsn for poorly soluble drugs
FH Faulding 1239831*
Suspension containing oxcarbazepine
Novartis 1239832*
Reconstitution of purified membrane proteins into preformed liposomes
Dade Behring 1239833*
Mixed structures resulting from the incorporation of biological macromolecule, especially of DNA, in a liquid crystal phase of amphiphiles, and vesicles obtained using these structures
Capsulis 1239834*
Pharmaceutical compsns providing enhanced drug concentrations
Pfizer Products 1239835*
Colloidal suspension of submicronic particles as vectors for active principles and method for preparing same
Flamel Technologies 1239836*
Direct compression polymer tablet core
Geltex Pharmaceuticals 1239837*
Method for tableting thickening systems
Henkel 1239838*
Hydrogel-driven layered drug dosage form comprising sertraline
Pfizer Products 1239839*
Antiviral medication
Alza 1239840*
Pharmaceutical formulations comprising sodium amoxycilline and potassium clavulanate
SmithKline Beecham 1239841*
Electrostatic application of powder material to solid dosage forms
Phoqus 1239842*
New (aminopropyl)methyl phosphinic acids
AstraZeneca 1239843*
Process for producing nanometer particles by fluid bed spray-drying
Kerkhof, Nicholas 1239844*
Hydroxide-releasing agents as skin permeation enhancers
Dermatrends 1239845*
Transdermal administration of phenylpropanolamine
Dermatrends 1239846*
Flat medicinal preparation for transmucosal administration of oxycodon or a compatible active ingredient in the oral cavity, for use in pain therapy and in addiction therapy
LTS Lohmann Therapie-Systeme 1239847*
Compsns and methods for modulating HDL cholesterol and triglyceride levels
University of British Columbia; Xenon Genetics 1239848*
Pharmaceutical formulations comprising resveratrol and use thereof
Pharmascience 1239849*
Use of carboxy compounds such as 2(4-acetoxyphenyl)-2-chloro-N-methyl-ethylammonium chloride as anti-inflammatory agents
Vlaams interuniversitair Instituut voor Biotechnologie 1239850*
Treatment of hyperproliferative disorders
Children's Hospital of Los Angeles 1239851*
Bissulphonamide derivatives as enzyme inhibitors
Arrow Therapeutics 1239852*
Fungicidal agent containing N-chlorotaurine and use thereof
Gottardi, Waldemar 1239853*
Use of a hyperglycemic agent for treating impaired glucose metabolism
Novartis 1239854*
Method for the prevention and/or treatment of atherosclerosis
Merck 1239855*
Sustained-release formulation of a cyclooxygenase-2 inhibitor
Pharmacia 1239856*
Dual-release compsns of a cyclooxygenase-2 inhibitor
Pharmacia 1239857*
The treatment of convulsive states
Medeva Europe 1239858*
Use of desloratadine for treating allergic and inflammatory conditions in paediatric patients
Schering 1239859*
Use of dextromethorphan and ocidase inhibitor for weaning patients from narcotics and antidepressants
Smith, Richard 1239860*
Combination of cyamemazine and an atypical neuroleptic
Aventis Pharma 1239861*
Pharmaceutical preparation for treating tumour diseases
Rhone-Poulenc Rorer 1239862*
Novel glycosidase inhibitors and their pharmacological uses, in particular for treating diabetes
Centre National de la Recherche Scientifique 1239863*
Treatment of heart rhythm disturbances with N6-substituted-5'-N-substituted) carboxamido-adenosines
Aderis Pharmaceuticals 1239864*
Pharmaceutical compsn for preventing and treating erectile dysfunction using purified sumsoo extract
Cheil Jedang Corp 1239865*
Inducing cellular immune responses to Her2/neu using peptide and nucleic acid compsns
Epimmune 1239866*
Methods for treating and preventing damage to mucosal tissue
University of Southern California 1239867*
Use of an immunosuppressant for increasing antifungal activity of a lipopeptide
Fujisawa Pharmaceutical 1239868*
Tweak receptor
Immunex Corp 1239869*
Interleukin-1 receptor antagonist-like molecules and uses thereof
Amgen 1239870*
Use of GLP-1 agonists for the inhibition of beta cell degeneration
Novo Nordisk 1239871*
Enzyme treatment for infection
Chemgen Corp 1239872*
Method for localised administration of fibrinolytic metalloproteinases
Amgen 1239873*
Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
Diadexus 1239874*
Procedure to use Staphylococcus bacteria
Gottfriesmottagningen 1239875*
Vaccine compsns
CSL; Chiron Corp 1239876*
Modulators of cytokine mediated signalling pathways and integrin alpha, beta receptor antagonists for combination therapy
BASF 1239877*
Formulations of adenosine A1 agonists
Glaxo Group 1239878*
Methods for preparing pharmaceutical formulations
Glaxo Group 1239884*
Interventions to mimic the effects of calorie restriction
The Regents of the University of California 1239885*
Labelled ascorbic acid derivatives
Amersham; Pither, Richard 1239886*
Cobalamin conjugates useful as imaging and therapeutic agents
Mayo Foundation for Medical Education 1239887*
